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Abstract
Elbow arthroplasty is increasingly performed in patients with rheumatic and post-traumatic arthritis. Data on elbow periprosthetic
joint infection (PJI) are limited. We investigated the characteristics and outcome of elbow PJI in a 14-year cohort of total elbow arthro-
plasties in a single centre. Elbow prosthesis, which were implanted between 1994 and 2007 at Schulthess Clinic in Zurich, were retro-
spectively screened for infection. PJI was deﬁned as periprosthetic purulence, the presence of sinus tract or microbial growth. A
Kaplan–Meier survival method and Cox proportional hazard analysis were performed. Of 358 elbow prostheses, PJI was identiﬁed in 27
(7.5%). The median patient age (range) was 61 (39–82) years; 63% were females. Seventeen patients (63%) had a rheumatic disorder
and ten (37%) had osteoarthritis. Debridement and implant retention was performed in 78%, followed by exchange or removal of the
prosthesis (15%) or no surgery (7%).The relapse-free survival (95% CI) was 79% (63–95%) after 1 year and 65% (45–85%) after 2 years.
The outcome after 2 years was signiﬁcantly better when patients were treated according to the algorithm compared to patients who
were not (100% vs. 33%, p <0.05). In 21 patients treated with debridement and retention, the cure rate was also higher when the algo-
rithm was followed (100% vs. 11%, p <0.05). The ﬁndings of the present study suggest that the treatment algorithm developed for hip
and knee PJI can be applied to elbow PJI. With proper patient selection and antimicrobial therapy, debridement and retention of the
elbow prosthesis is associated with good treatment outcome.
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Introduction
Elbow arthroplasty is increasingly used for treatment of
post-traumatic arthritis and chronic inﬂammatory joint
disease, such as rheumatic and psoriatic arthropathy [1]. After
ﬁrst successful implantation in the early 1970s [2], elbow
prostheses underwent continuous reﬁnements with respect to
the implant design and surgical techniques. Currently, aseptic
(mechanical) prosthesis loosening, joint instability, ulnar
neuropathy and periprosthetic joint infection (PJI) remain a
continuous challenge [1,3,4].
Data on elbow PJI are limited because only small case
series were published, and non-uniform deﬁnitions and vari-
able follow-up periods were used [5–10]. The incidence of
elbow PJI is reported to be in the range 3–11%, which is
higher than for hip or knee arthroplasties. Moreover, elbow
joints have several distinctive differences, such as no weight-
bearing function, and hence they seldom develop degenera-
tive arthritis, and have scarce surrounding soft tissue with a
higher risk for contiguous infection extending from tissue
dehiscence [5].
The optimal surgical and antimicrobial treatment approach
for elbow PJI has not yet been determined. Therefore, we
investigated the characteristics and outcome of elbow PJI in
a 14-year cohort of total elbow arthroplasties in a single cen-
tre. We speciﬁcally focused on the appropriateness of the
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treatment algorithm, which was developed for hip and knee
PJI [11]. In this algorithm, the type of surgical procedure
(debridement and retention vs. a one or two stage
exchange) and the antimicrobial therapy (type of antibiotic
and duration) are deﬁned by a combination of clinical, radio-
logical and microbiological criteria.
Patients and Methods
Study population
The Schulthess Clinic is a specialized 160-bed orthopaedic
centre and a reference institution for elbow surgery, including
primary and revision arthroplasties. A total of approximately
7500 surgical procedures are performed annually. All elbow
arthroplasties performed at the Schulthess Clinic, Zurich,
Switzerland, are consecutively included in the elbow cohort.
For the present study, all elbow prostheses implanted between
January 1994 and December 2007 were retrospectively
reviewed. All episodes, which fulﬁlled the predetermined
criteria for PJI (below) were included. In patients with sugges-
tive signs or symptoms for elbow PJI, at least one invasive
diagnostic attempt to detect the potential pathogen was
performed. The Infectious Diseases Service was consulted
throughout the study duration. The study protocol was
approved by the Institutional Review Board.
Deﬁnitions
Elbow PJI was diagnosed, if one or more of the following
criteria were fulﬁlled: (i) visible purulence of a preoperative
aspirate or intraoperative periprosthetic tissue (as determined
by the surgeon); (ii) presence of a sinus tract communicating
with the prosthesis; (iii) microbial growth in a preoperative
joint aspirate, intraoperative periprosthetic tissue or sonica-
tion ﬂuid of the removed implant; or (iv) synovial ﬂuid with
>1700 leukocytes/lL or >65% granulocytes, as determined in
previous studies for knee PJI [12]. Similar diagnostic criteria
for PJI were used in studies involving various types of joint
prostheses [11,13–17]. Acute inﬂammation in periprosthetic
tissue sections was not used as diagnostic criterion in the
present study as a result of a high prevalence of underlying
rheumatologic joint disorders, which may mimic infection. For
low-virulent organisms, such as coagulase-negative staphylo-
cocci or Gram-positive anaerobes, growth of the same organ-
ism in at least two independent specimens was required.
According to the route of infection, episodes were classi-
ﬁed as contiguous, perioperative or haematogenous [18].
Contiguous infection was determined if skin breakdown
overlying the elbow prosthesis or preceding open trauma
occurred. Perioperative infections were classiﬁed into early
(within 3 months after surgery) or delayed (3–24 months). A
haematogenous infection was diagnosed if blood cultures
were positive with a distant source or haematogenous seed-
ing was suspected by acute clinical presentation with fever,
pain and redness of the elbow joint in late infections.
Microbiological diagnosis
Aspirated ﬂuid and intraoperative periprosthetic tissue speci-
mens were cultured on aerobic and anaerobic blood agar
plates, and incubated at 35C for 7 days (until July 2006) or
for 10 days (after July 2006). In addition, thioglycollate broth
was cultured for 10 days. Isolated microorganisms were
identiﬁed and their antimicrobial susceptibility tested using
standard microbiological techniques.
In addition, elbow prostheses explanted after January 2007
were sent for sonication to improve the detection of bioﬁlm
bacteria [15]. In brief, the explanted elbow prostheses was
aseptically removed in the operating room and transported
to the microbiology laboratory in air-tight polyethylene con-
tainers (Lock & Lock, Vetrag AG, Sta¨fa, Switzerland). In the
microbiological laboratory, Ringer’s solution was added in
the containers and the prostheses were processed within
48 h of removal by vortexing (30 s) and sonication (1 min)
using an ultrasound bath (BactoSonic, Bandelin GmbH, Berlin,
Germany; http://www.bactosonic.info) at a frequency of
40 ± 2 kHz and a power density of 0.22 ± 0.04 W/cm2. The
resulting sonication ﬂuid was vortexed again to homogenous-
ly distribute the sonication ﬂuid, which was plated in aliquots
of 0.1 mL onto aerobic and anaerobic sheep blood agar
plates and 3 mL in 7 mL in thioglycollate broth. Cultures
were incubated at 37C for 7 days and inspected daily for
bacterial growth.
Surgical treatment
The approach was individually determined at surgeon’s dis-
cretion. In the case of PJI, the type of revision was chosen
among three potential approaches: (i) debridement and
implant retention; (ii) one-stage; or (iii) two-stage exchange
of the implant. We retrospectively determined whether the
surgeon’s decision was in agreement with the treatment
algorithm for hip and knee PJI [11]. According to this algo-
rithm, the least invasive surgical treatment should be used,
whereas retention of the implant is allowed only if all of the
following four conditions were fulﬁlled: (i) short duration of
infection, including early postoperative infection (within
3 months after surgery) or acute haematogenous infection;
(ii) short duration of clinical signs (not longer than 21 days);
(iii) not severely damaged surrounding soft tissue; and (iv)
the availability of antimicrobial agents active against bioﬁlms
(e.g. rifampin for staphylococci and quinolones for Gram-neg-
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ative rods). If one or more of these conditions were not ful-
ﬁlled, retention of the implant was considered inappropriate
and the implant needed to be exchanged. The exchange
could be accomplished in one stage (in the case of intact soft
tissue and the absence of difﬁcult-to-treat organisms) or in
two stages (in all other situations). Difﬁcult-to-treat organ-
isms included rifampin-resistant staphylococci, enterococci,
nutritionally variant streptococci (Abiotrophia and Granulicatel-
la spp.), quinolone-resistant Gram-negative rods and fungi.
Antimicrobial treatment
As for surgical treatment, we retrospectively determined
whether the antimicrobial therapy was in agreement with
the treatment algorithm [11]. The appropriateness of the
antimicrobial regime was determined according to the type
of organism, its susceptibility and the chosen surgical modal-
ity [11]. Antimicrobial treatment was considered appropriate,
if an initial intravenous treatment was administered for initial
2 weeks, followed by oral treatment. The total duration of
antimicrobial treatment was 3 months if the implant was
retained or a two-stage exchange with short interval
(2 weeks) was performed. In this case, a rifampin-combina-
tion regime was required for staphylococcal PJI. In case of
two-stage exchange with long interval, antimicrobial treat-
ment was administered for at least 6–8 weeks (rifampin was
not required), followed by an antibiotic-free period of at
least 2 weeks before reimplantation.
Outcome evaluation
Patients were evaluated regarding signs and symptoms of
infection and functional outcome in the orthopaedic outpa-
tient clinic during regularly scheduled visits at 3 months,
6 months, and 1, 2, 5 and 10 years after surgery. Only
patients with at least 1 year of follow-up were evaluated
in the present study. Follow-up evaluations included clinical
examination, laboratory investigations and plain X-ray of
the prosthetic elbow (at the discretion of the orthopaedic
surgeon). In addition to orthopaedic follow-up, patients
with elbow PJI were independently contacted by phone by
one of investigators (Y.A.) and speciﬁcally interviewed
for signs and symptoms of PJI, such as pain, redness or
swelling.
Statistical analysis
The probability of relapse-free survival and the 95% CI was
estimated using the Kaplan–Meier survival method. Cox pro-
portional hazard analysis was used for comparison of
relapse-free survivals of subgroups. Statistical calculations
were performed with the SAS software package, version 8.2
(SAS Institute Inc., Cary, NC, USA) and graphic analysis was
conducted using ORIGINPRO, version 8 (Origin Lab Corp.,
Northampton, MA, USA).
Results
Characteristics of 358 patients included in the elbow cohort
Underlying joint disorders were rheumatic disease in 203
episodes (57%) and osteoarthritis in 155 episodes (43%)
(Table 1). At the time of implantation, no differences were
observed regarding patient age, gender, underlying joint dis-
order or type of arthroplasty between patients who have
developed elbow PJI and those which have not.
Characteristics of 27 patients with elbow PJI
Of 358 cases, 27 (7.5%) developed elbow PJI (median age at
the time of infection was 61 years, range 39–82 years, 63%
were females). In 24 of 27 cases (88%) a Gschwend–Scheier–
Ba¨hler III (GSB III) elbow prosthesis was implanted [19]
(Table 2). The median time between the last surgical proce-
dure of the elbow and time of infection was 6 months
(range 0.6–162 months). The median time from primary
implantation to time of infection was 45 months (range 0.6–
183 months).
Microbiology
In the majority (26 of 27 patients), microbial growth was
detected preoperatively and/or intraoperatively. In the one
patient with negative cultures, sinus tract with purulent dis-
charge was observed and intraoperatively abundant pus
around the prosthesis was noted. Table 3 summarizes the
causing microorganisms. In ﬁve patients, S. aureus was found
as the cause of haematogenous infection. Microbiological
TABLE 1. Characteristics of 358 elbow prostheses at time
of implantation, which were included in the elbow cohort
Characteristics Value
Median age (range), years 60 (20–83)
Female gender 216 (60%)
Underlying joint disorder
Rheumatic 203 (57%)
Rheumatoid arthritis 196
Psoriasis arthropathy 7
Osteoarthritis 155 (43%)
Post-traumatic arthritis 92
Primary osteoarthritis 13
Other 49
Type of arthroplasty
Primary 262 (68%)
Revisiona 96 (32%)
Values are given as n (%), if not indicated otherwise.
aRevisions not as a result of infection included a total exchange of the elbow
prosthesis (n = 76), elongation of the ulnar component (n = 15) and partial
exchange of the ulnar component (n = 5).
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diagnosis was made by periprosthetic tissue biopsies in 18
(66%), intraoperative swabs in three (11%), synovial ﬂuid in
six (21%) and sonication ﬂuid culture in one (4%).
Treatment strategy
Surgical treatment modalities are summarized in Table 2. In
78% of cases (n = 21), debridement and implant retention
was performed; in four cases, the prosthesis was exchanged
in one (n = 1) or two stages (n = 2), one prosthesis was
resected (no reimplantation) and, in two cases, no surgery
was performed (only antibiotics). Both patients with a two-
stage exchange had an implant-free interval of 16 and
28 weeks, respectively; both received prolonged antimicrobial
therapy for 3 months followed by an antibiotic-free interval
prior to reimplantation. The medium duration of antimicro-
bial therapy was 3 months with a range of 0.5–16 months.
Initially, intravenous therapy of at least 2 weeks was adminis-
tered in 24 of 27 cases (89%). All patients received a combi-
nation therapy with rifampin, if staphylococci were isolated
and the prosthesis was retained (Table 4).
Outcome evaluation
At follow-up, 19 (70%) patients were free of infection (med-
ian follow-up time 2.7 years, range 1.0–11.3 years) and eight
(30%) had a relapse (median time to relapse 0.56 years,
TABLE 2. Characteristics of 27 episodes of elbow peripros-
thetic joint infection (PJI)
Characteristics Number (%) of episodes
Median age (range), years 61 (39–82)
Female 17 (63%)
Underlying joint disorder
Rheumatic 17 (63%)
Osteoarthritis 10 (37%)
Type of arthroplasty
Primary 19 (70%)
Revision 8 (30%)
Type of elbow prosthesis
GSB III 24 (88%)
Coonrad–Morrey 2 (7%)
Discovery 1 (4%)
Manifestation of PJI after last surgery
Early (<3 months) 14 (48%)
Delayed (3–24 months) 3 (11%)
Late (>24 months) 11 (40%)
Route of infection
Haematogenous 8 (30%)
Perioperative 16 (59%)
Contiguousa 3 (11%)
Surgical treatment
Debridement with implant retention 21 (78%)
One-stage exchange 1 (4%)
Two-stage exchangeb 2 (7%)
Resection arthroplasty 1 (4%)
No surgery (antibiotics only) 2 (7%)
GSB, Gschwend–Scheier–Ba¨hler [19].
aSkin breakdown was present in the region overlying the prosthesis.
bBoth patients with a two-stage exchange had an implant-free interval of 16 and
28 weeks, respectively.
TABLE 3. Microbiology of 27 episodes of elbow peripros-
thetic joint infection
Microbiological characteristics Number (%) of episodes
Single microorganism
Staphylococcus aureusa 11 (41%)
Coagulase-negative staphylococcib 9 (33%)
Streptococcus agalactiae 2 (7%)
Enterobacter cloacae 1 (3.7%)
Corynebacterium pseudodiphtheriticum 1 (3.7%)
Polymicrobialc 2 (7%)
No organism 1 (3.7%)
Percentages are rounded and may not add up to 100%.
aNo methicillin-resistance was observed in S. aureus.
bStaphylococcus epidermidis (n = 6), Staphylococcus capitis (n = 2), Staphylococcus
caprae (n = 1). Methicillin-resistance was observed in eight of 11 (73%) isolates
of coagulase-negative staphylococci (including those from polymicrobial infec-
tions).
cMethicillin-resistant S. epidermidis and E. cloacae in one episode; methicillin-resis-
tant S. epidermidis and S. aureus (methicillin-susceptible) in one episode.
TABLE 4. Intravenous and oral antimicrobial treatment of
27 episodes of elbow periprosthetic joint infection
Intravenous antimicrobial
treatment Oral antimicrobial treatment
Antibiotic (s)
Number
of cases Antibiotic (s)
Number
of cases
Amoxicillin-clavulanate/
rifampin
7 Ciproﬂoxacin/rifampin 14
Flucloxacillin/rifampin 8 Levoﬂoxacin/rifampin 4
Vancomycin/rifampin 6 Linezolid 1
Vancomycin/impenem/
rifampin
1 Amoxicillin 2
Imipenem/rifampin 1 Fucidin/rifampin 1
Teicoplanin 1 Ciproﬂoxacin 1
Amoxicillin-
clavulanate/rifampin
1
No intravenous therapy 3 No oral therapy 3
FIG. 1. Relapse-free survival of 27 elbow periprosthetic joint infec-
tion. The dotted lines represent the 95% CI. The relapse-free sur-
vival (95% CI) was 79% (63–95%) after 1 year and 65% (45–85%)
after 2 years.
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range 0.1–1.3 years. Fig. 1 shows a relapse-free survival of
elbow PJI, which was 79% (95% CI 63–95%) after 1 year and
65% (95% CI 45–85%) after 2 years. Among 21 patients trea-
ted with debridement and retention, 13 cases (62%) were
free of infection and eight cases (38%) experienced a relapse
of the infection. Overall, ﬁve of 27 (19%) patients with PJI
died; one patient due to infectious endocarditis with second-
ary haematogenous elbow PJI, two due to sepsis of the hip
or knee PJI and two for non-infectious reasons.
Patients without a relapse of infection were interviewed
regarding functional outcome in January 2009. The majority
of patients (13 of 19; 68%) were satisﬁed with the function
of the elbow prosthesis and did not report any local
inﬂammatory symptoms. Two patients complained about
diminished muscle strength and one patient reported persis-
tent joint effusion; all three were without suspicion of
elbow PJI.
Evaluation of the treatment outcome with respect to the
treatment algorithm
If the treatment algorithm was followed (in 15 episodes), the
relapse-free survival was 100%. By contrast, if the algorithm
was not followed (in 12 episodes), the relapse-free survival
was 58% after 1 year and 33% after 2 years (Fig. 2)
(p <0.05). In 21 patients treated with debridement and
retention, the cure rate was higher when the algorithm was
followed (12 of 12 cases; 100%) than in patients where the
algorithm was not followed (one of nine; 11%) (p <0.05).
In all eight patients with infection relapse, either antimi-
crobial therapy or surgical procedure (or both) was not in
accordance with the recommended algorithm (Table 5). In
patients with an infection relapse, debridement and implant
retention was performed instead of two-stage exchange
(two patients with delayed, three with late contiguous infec-
tion and one patient with early infection but duration of
symptoms of more than 3 weeks). Moreover, a shorter then
suggested antimicrobial treatment duration was used
(2 months instead 3 months) in episodes with debridement
and retention or the patient prematurely discontinued the
antibiotic therapy.
Discussion
No standard surgical and antimicrobial treatment standard
approach exists for elbow PJI. Therefore, we retrospectively
investigated elbow PJI in a cohort of 358 elbow arthroplasty
during a 14-year-period in a single institution. The infection
rate of elbow PJI was 7.5%. This is comparable to the rates
reported by Morrey et al. [8] (9%), Wolfe et al. [9] (7.3%)
and Schmidt et al. [4] (10.3%), and is higher than that
reported by Yamaguchi et al. [7] (3.2%) and Gille et al.
FIG. 2. Relapse-free survival of elbow periprosthetic joint infection
stratiﬁed if treated (n = 15) or not (n = 12) according to the treat-
ment algorithm. The outcome after 2 years was signiﬁcantly better
when treated according to the algorithm than in patients who were
not (100% vs. 33%, p <0.05).
TABLE 5. Elbow periprosthetic joint infection (PJI) with relapse of infection: differences between recommended and per-
formed antimicrobial and surgical procedure
Number Type of infectiona Infecting organism initially Infecting organism at relapse Recommended procedure Performed procedure
1 Early (2 months) Staphylococcus aureus S. aureus AB 3 months AB 2 months
2 Early (1 months) Staphylococcus agalactiae S. agalactiae AB 3 months Noncompliance for AB
3 Early, symptoms >3 weeks,
soft tissue-compromised
CNS, Enterobacter cloacae E. cloacae 2-stage exchange Debridement and retention
4 Delayed (6 months) CNS CNS 3 months Retention, AB 2 months
5 Delayed (8 months) E. cloacae Mixed (E. cloacae, CNS) 2-stage exchange,
AB 3 months
Retention, AB 1 months
6 Late contiguous (8.7 years) CNS CNS 2-stage exchange Retention
7 Late contiguous (9 years) CNS Mixed (CNS, Micrococcus spp.) 2-stage exchange Retention
8 Late contiguous (4.2 years) CNS CNS 2-stage exchange Retention, no intravenous
therapy
CNS, coagulase-negative staphylococci; AB, antibiotics.
aTime (in parenthesis) denotes the duration between elbow implantation and the manifestation of elbow PJI.
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(1.9%) [6]. The higher infection rates in elbow arthroplasty
compared to hip (<1%) and knee prostheses (<2%) may be
due to several reasons. First, the main reason for a hip or
knee arthroplasty is the degenerative osteoarthritis, whereas,
in elbow arthroplasties, the main underlying disorder is rheu-
matic or post-traumatic osteoarthritis. Rheumatic disorders
are associated with a higher risk for infection as a result of
chronic inﬂammatory progress and immunosuppressive treat-
ment [5,6,20]. Second, the subcutaneous placement and lack
of muscle coverage of the elbow prosthesis provides little
protection against contiguous infection after bursitis or skin
breakdown. Third, soft tissue is more vulnerable and prone
to infections in patients with post-traumatic or rheumatologic
arthritis than in healthy individuals [4]. And last, multiple
reconstructive procedures prior to elbow arthroplasty for
posttraumatic osteoarthritis are associated with a higher risk
of infection.
In the present study, the most frequently isolated patho-
gen was S. aureus (41%) followed by coagulase-negative
staphylococci (33%), which is in accordance with other stud-
ies [6,7,9,10]. Interestingly, no Propionibacterium acnes was
isolated despite the optimized diagnostic procedure. We
speculate that lower density of sweat glands at the elbow
region compared to shoulder may explain this difference
[21,22].
The relapse-free-survival in the present study was 65% at
2 years. All eight relapses occurred within 15 months of anti-
biotic treatment. Furthermore, the cure rate at 2 years was
only 33% when the algorithm was not followed compared to
100% when the treatment was in agreement of the algorithm
(p <0.05). This observation is important because the algo-
rithm was developed for treatment of hip and knee PJI and
has never been evaluated in patients with elbow PJI. Patients
with elbow arthroplasty might represent a unique population
as a result of technical challenges in revision surgery and the
underlying comorbidity. The results are especially important
in patients treated with debridement and retention of the
prosthesis, in whom the cure rate was also signiﬁcantly
higher when the algorithm was followed than in patients
where the algorithm was not followed (100% vs. 11%,
p <0.05).
The algorithm was developed on the basis of studies per-
formed in vitro, animal models of foreign body infections
[23,24] and clinical studies [25,26]. The cure rate in other
studies following the algorithm was 94.3% after knee arthro-
plasty [27], 83% [28] and 91% [29] after hip arthroplasty,
and 100% in a population with different orthopaedic devices
[26]. However, when the algorithm was not followed, the
cure rates were signiﬁcantly lower, in the range 57–60%
[27,30]. The most common deviations from the proposed
algorithm were the improper selection of patients for
implant retention (e.g. loose implants in delayed infections)
or a lack of use of rifampin-containing regimens in staphylo-
coccal PJI (7–9). Rifampin is an essential factor for the eradi-
cation of staphylococcal bioﬁlms when prosthesis retention
is attempted or a two-stage exchange with a short interval is
used.
A strength of the present study is the systematic analysis
of a cohort of 358 elbow arthroplasties in a single centre
with four dedicated elbow surgeons using similar surgical
techniques and postoperative management. Limitations are
the retrospective design and the low number of patients
with a relapse of infection, which does not allow risk factor
analysis. Nevertheless, the present study suggests a high
probability of long-term success if the treatment algorithm is
followed. This ﬁnding needs to be conﬁrmed in larger
cohorts with a longer follow-up period.
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